Richard Thomas Williams - 11 Mar 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Chief Medical Officer
Signature
/s/ Mark Meltz, attorney in fact
Issuer symbol
N/A
Transactions as of
11 Mar 2022
Net transactions value
+$338,850
Form type
4
Filing time
15 Mar 2022, 17:01:19 UTC
Previous filing
15 Feb 2022
Next filing
02 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Purchase $129,600 +15,000 +643% $8.64 17,333 11 Mar 2022 Direct F1, F2
transaction KNTE Common Stock Purchase $209,250 +25,000 +144% $8.37 42,333 14 Mar 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.42 to $8.77, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 Includes 1,769 shares acquired under the Issuers Employee Stock Purchase Plan (the "Plan") in May 2021 and 564 shares acquired under the Plan in November 2021.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.25 to $8.50, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.